Key facts
- It has raised $250K; the latest was Later Stage VC in Jul 2025.
- Notable investors include Natural Products Canada, Innotech Alberta, Lesaffre, National Research Council Canada, Pet Wellness Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CanBiocin
- ·The full record, as it builds
Funding rounds
No funding rounds for CanBiocin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CanBiocin
Producer of natural probiotic products intended to maintain pets' immune systems and intestinal health. The company's products are mixtures and bacteriocins-based products that have neurotransmitters and metabolites to fight against bacteria causing major gastrointestinal illness and keep the gastrointestinal tract calm during times of stress, enabling pet owners to keep their pets healthy.
- Sector
- Business Products and Services (B2B)
- HQ
- Edmonton, Canada
- Founded
- 1998
- Employees
- 16
- Website
- canbiocin.ca/
- Ownership
- Privately Held (backing)
CanBiocin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CanBiocin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CanBiocin in its N-PORT filings yet. We sweep new filings monthly.